newsfilter
← Latest News
Business Wire·

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Silence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30,